ZEALAND PHARMA A/S financials

ZEALAND PHARMA A/S

Country: DK Reporting currency: DKK Latest annual report: 2026-03-31

LEI: 549300ITBB1ULBL4CZ12 ISIN: DK0060257814

Financial statements (DKK, as reported — unscaled; 75 line items across 3 annual periods)

Line item	2026	2025	2025
Income statement
Revenue	DKK 34.0M	—	DKK 8.0M
Cost of sales	DKK 0	—	DKK 0
Gross profit	DKK 34.0M	—	DKK 8.0M
Operating profit (EBIT)	-DKK 539.0M	—	-DKK 406.0M
Finance costs	DKK 27.0M	—	DKK 20.0M
Profit before tax	-DKK 394.0M	—	-DKK 336.0M
Income tax expense	DKK 0	—	-DKK 1.0M
Profit for the year	-DKK 394.0M	—	-DKK 335.0M
Total comprehensive income	-DKK 394.0M	—	-DKK 335.0M
Per share
Basic EPS	DKK -5.58	—	DKK -4.74
Diluted EPS	DKK -5.58	—	DKK -4.74
Free cash flow / share	DKK -9.66	—	DKK -7.17
Cash flow statement
Net cash from operating activities	-DKK 672.0M	—	-DKK 501.0M
Income taxes paid	DKK 0	—	DKK 0
Net cash from investing activities	-DKK 116.0M	—	DKK 555.0M
Purchase of PP&E (capex)	DKK 10.0M	—	DKK 6.0M
Purchase of intangibles	DKK 1.0M	—	DKK 2.0M
Net cash from financing activities	-DKK 8.0M	—	-DKK 1.0M
Lease liability payments	DKK 9.0M	—	DKK 4.0M
Net change in cash	-DKK 796.0M	—	DKK 53.0M
Balance sheet
Total assets	DKK 15.30B	DKK 15.95B	—
Non-current assets	DKK 283.0M	DKK 279.0M	—
Property, plant & equipment	DKK 77.0M	DKK 70.0M	—
Right-of-use assets	DKK 87.0M	DKK 82.0M	—
Current assets	DKK 15.02B	DKK 15.67B	—
Trade & other receivables	DKK 106.0M	DKK 174.0M	—
Cash & equivalents	DKK 3.85B	DKK 4.58B	DKK 776.0M
Total equity	DKK 14.47B	DKK 14.83B	DKK 8.31B
Non-current liabilities	DKK 428.0M	DKK 453.0M	—
Long-term borrowings	DKK 307.0M	DKK 303.0M	—
Lease liabilities (non-current)	DKK 78.0M	DKK 80.0M	—
Current liabilities	DKK 404.0M	DKK 665.0M	—
Lease liabilities (current)	DKK 29.0M	DKK 23.0M	—
Derived metrics
Free cash flow	-DKK 682.0M	—	-DKK 507.0M
Operating margin	-1585.3%	—	-5075.0%
Net margin	-1158.8%	—	-4187.5%
Return on equity	-2.7%	—	-4.0%
Cash conversion ratio	1.71×	—	1.50×
Capex coverage	-67.20×	—	-83.50×
Other reported items
Current Deferred Income Including Current Contract Liabilities	DKK 33.0M	DKK 65.0M	—
Current Financial Assets At Fair Value Through Profit Or Loss	DKK 10.62B	DKK 10.53B	—
Current Prepayments	DKK 311.0M	DKK 242.0M	—
Current Tax Assets Current	DKK 31.0M	DKK 31.0M	—
Deferred Tax Assets	DKK 1.0M	DKK 1.0M	—
Effect of Exchange Rate Changes On Cash and Cash Equivalents	DKK 68.0M	—	-DKK 3.0M
Equity and Liabilities	DKK 15.30B	DKK 15.95B	—
Finance Costs Paid Classified As Operating Activities	DKK 3.0M	—	DKK 3.0M
Finance Income	DKK 172.0M	—	DKK 90.0M
Finance Income Received Classified As Operating Activities	DKK 76.0M	—	DKK 60.0M
General and Administrative Expense	DKK 82.0M	—	DKK 65.0M
Increase Decrease In Working Capital	DKK 280.0M	—	DKK 181.0M
Increase Decrease Through Exercise of Warrants Equity	DKK 1.0M	—	DKK 3.0M
Increase Decrease Through Sharebased Payment Transactions	DKK 32.0M	—	DKK 23.0M
Intangible Assets Other Than Goodwill	DKK 45.0M	DKK 45.0M	—
Issued Capital	DKK 72.0M	DKK 72.0M	—
Liabilities	DKK 832.0M	DKK 1.12B	—
Miscellaneous Other Operating Expense	DKK 0	—	DKK 22.0M
Noncurrent Derivative Financial Liabilities	DKK 43.0M	DKK 70.0M	—
Noncurrent Prepayments	DKK 53.0M	DKK 61.0M	—
Operating Expense Excluding Cost of Sales	DKK 573.0M	—	DKK 414.0M
Other Adjustments For Noncash Items	-DKK 71.0M	—	-DKK 42.0M
Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities	DKK 0	—	DKK 24.0M
Other Comprehensive Income Net of Tax Exchange Differences On Translation	DKK 0	—	DKK 0
Other Current Payables	DKK 82.0M	DKK 230.0M	—
Other Current Receivables	DKK 102.0M	DKK 114.0M	—
Other Noncurrent Receivables	DKK 20.0M	DKK 20.0M	—
Proceeds From Exercise of Warrants	DKK 1.0M	—	DKK 3.0M
Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities	DKK 3.69B	—	DKK 3.10B
Purchase of Financial Instruments Classified As Investing Activities	DKK 3.80B	—	DKK 2.56B
Research and Development Expense	DKK 469.0M	—	DKK 290.0M
Reserve of Exchange Differences On Translation	DKK 23.0M	DKK 24.0M	—
Retained Earnings	-DKK 356.0M	DKK 6.0M	—
Sales and Marketing Expense	DKK 22.0M	—	DKK 37.0M
Share Premium	DKK 14.73B	DKK 14.73B	—
Trade and Other Current Payables To Trade Suppliers	DKK 260.0M	DKK 347.0M	—

Methodology

Every line item above is a fact tagged in ZEALAND PHARMA A/S's annual report filed in the European Single Electronic Format (ESEF) under the IFRS taxonomy (ifrs-full) — the income statement, balance sheet and cash-flow statement as the filer reported them. Values are shown as-is, in the reporting currency (DKK), without rescaling; the row labels map to the underlying concept name (e.g. Revenue → ifrs-full:Revenue, Operating profit → ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS → ifrs-full:DilutedEarningsLossPerShare), and any concept without a curated label is shown under “Other reported items” with its de-camel-cased tag name. Only consolidated, default-member facts are shown (segment / dimensional breakdowns are excluded).

“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.

Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.